1stOncology™: Cancer Intelligence Service – Page 72 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

On May 28, 2026 Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) reported continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization ("CRO"), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into a revenue-generating healthcare enterprise comprised of Tevogen Bio, its biotechnology arm; Tevogen.AI, its technology arm; and, subject to completion of proposed transactions, a healthcare services arm that may include management services and contract research operations.

"Capital discipline and preserving the integrity of our capital structure are core priorities for us," said Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio. "Our strategic objective is to build a financially self-sufficient healthcare enterprise with the financial strength to support operations, advance growth initiatives, and create long-term value through revenue generation. The acquisition opportunities we are evaluating represent an initial phase of that strategy, and any related capital allocation decisions will continue to be guided by strategic fit, long-term value creation, and disciplined stewardship of Tevogen’s capital structure."

The proposed transactions remain subject to, among other things, completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions. There can be no assurance that any such transaction will be consummated.

(Press release, Tevogen Bio, MAY 28, 2026, View Source [SID1234666178])

Parexel to Present Real-World Oncology Research and Launch New Patient-Focused Campaign at ASCO 2026

On May 28, 2026 Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry, reported two virtual research posters accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, May 29-June 2, in Chicago. The research examines critical challenges in oncology drug development and real-world safety outcomes for a HER2-targeted therapy, grounding Parexel’s ASCO (Free ASCO Whitepaper) presence in the evidence that advances cancer care. The company also unveiled From Insights to Life, a new patient-focused creative campaign reflecting Parexel’s commitment to helping sponsors advance their programs so patients can return to what matters most to them.

Virtual Poster Presentations

As part of ASCO (Free ASCO Whitepaper) 2026, Parexel is presenting two virtual research posters, one analyzing common deficiencies in oncology marketing applications that lead to FDA rejections and another focused on the pulmonary safety profile of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer.

Virtual Poster: Deficiencies in oncology marketing applications leading to FDA rejections: An assessment of complete response letters
Virtual Poster: Real-World Risk of Interstitial Lung Disease and Pneumonitis with Trastuzumab Deruxtecan vs Trastuzumab in HER2-Positive Metastatic Breast Cancer: A Propensity Score-Matched Analysis

Parexel’s oncology experience over the past five years spans more than 560 clinical studies, more than 104,000 patients and more than 26,000 sites across more than 50 countries. Over that same period, Parexel Biotech delivered the data supporting six U.S. Food and Drug Administration (FDA) and three European Medicines Agency (EMA) new solid-tumor oncology drug approvals.

"ASCO is where the oncology community comes together to advance science that matters for patients, and Parexel’s presence reflects that same commitment," said Jozsef Palatka, M.D., Senior Vice President and Global Therapeutic Head of Oncology at Parexel, who will lead the company’s on-site activities at the meeting. "The research we are presenting exemplifies the rigor we bring to every program. Translating real-world evidence into confident clinical development decisions is how we help sponsors advance therapies forward for the patients who need them."

Joining Dr. Palatka on-site will be Charlotte Moser, Chief Medical Officer, Jim Anthony, Chief Commercial Officer and President, Parexel Biotech, Stacy Hurt, Chief Patient Officer, Mike D’Ambrosio, Senior Vice President and Global Head of Real World Research, and members of Parexel’s medical, commercial and marketing teams.

From Insights to Life

The company also announced the launch of From Insights to Life, a new patient-focused creative campaign centered on real people, representing different disease states and demographics, navigating the space between a medical diagnosis and daily living. Inspired by patient experiences and driven by a sense of purpose, the campaign reaffirms Parexel’s commitment to delivering clinical trials that support patients in continuing to live the lives they love.

"What patients want most is to feel genuinely seen by the people working on their behalf, recognized for the full life they are striving to return to," said Stacy Hurt, Chief Patient Officer at Parexel. "At Parexel, truly listening to patients is the principle that guides every decision we make, every trial we design and every partnership we form. From Insights to Life captures something I have felt throughout my relationship with Parexel—when patients are placed at the center of everything we do, it fundamentally changes what is possible. It’s the difference between advancing science and creating solutions that genuinely change people’s lives."

From Insights to Life builds on the foundation of Parexel’s award-winning Insights Generation Engine campaign, which was recognized by PR Week’s 2026 Corporate Healthcare Campaign Award. Where Insights Generation Engine celebrates the expertise of Parexel’s colleagues, From Insights to Life extends that commitment outward to the patients who Parexel serves.

The campaign will roll out throughout 2026 with additional original compositions unveiled across Parexel’s website, digital and social channels, and activations at milestone biopharmaceutical industry events, such as the American Diabetes Association and the World Orphan Drug Congress. Each new patient-focused campaign image reinforces Parexel’s mission—translating insight into meaningful impact across the clinical development journey and accelerating life-changing medicines to patients.

(Press release, PAREXEL International, MAY 28, 2026, View Source [SID1234666177])

CG Oncology to Present at Upcoming Investor Conferences in June

On May 28, 2026 CG Oncology, Inc. (NASDAQ: CGON) reported that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:

Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Presentation Time: 10:30-11:00 AM ET
Location: New York, New York

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2026
Presentation Time: 2:40-3:15 PM ET
Location: Miami, Florida

Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company’s website at www.cgoncology.com. The webcast replays will be available shortly after the conclusion of the live presentations and archived for approximately 90 days.

(Press release, CG Oncology, MAY 28, 2026, View Source [SID1234666176])

Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026

On May 28, 2026 Molecular Targeting Technologies, Inc. (MTTI) reported the clinical findings of the Next-Generation PRRT, ¹⁷⁷Lu-DOTA-EB-TATE to treat GEP-NET Patients. The Phase 1 dose-escalation and dosimetry study will be presented at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place May 29–June 3, 2026, in Los Angeles, California.

Neuroendocrine tumors (NETs) are often detected late, limiting curative treatments and requiring systemic therapies like Peptide Receptor Radionuclide Therapy (PRRT). While 177Lu-DOTATATE has demonstrated efficacy, its rapid clearance limits tumor radiation delivery and may increase renal toxicity risk.

"Our Clinical findings suggest that EBTATE may achieve meaningful clinical responses after only two treatment cycles while delivering approximately 12.5% of the cumulative radioactivity required for standard PRRT," said Chris Pak, Chairman and Chief Executive Officer of MTTI. "If validated in larger studies, EBTATE could represent a transformative advance in radiopharmaceutical therapy, shortening treatment duration, reducing radiation exposure, and enabling physicians to evaluate efficacy much earlier than is possible today."

"EBTATE achieved substantially higher tumor uptake and prolonged retention than conventional ¹⁷⁷Lu-DOTATATE while maintaining a favorable safety profile, with no kidney toxicity observed for one year follow-up," said Lisa Bodei, MD, PhD, a nuclear medicine physician at Memorial Sloan Kettering Cancer Center. "The ability to deliver greater tumor radiation with significantly less administered radioactivity positions EBTATE as a potentially transformative PRRT. These data also support the possibility of a streamlined two-cycle regimen, enabling earlier evaluation of treatment efficacy."

The presentation entitled, "Next-Generation PRRT" by Dr. Bodei (poster # 261874). The poster has also been selected for a 10-minute oral presentation during the 2026 Patient Education Day NETS Program Schedule (View Source), on 5/31/26 during the SNMMI meeting.

MTTI will present its proprietary Evans Blue (EB) albumin-binding technology platform at Booth #1758 during the SNMMI Annual Meeting, featuring clinical data from 81 GEP-NET patients and compelling preclinical results.

MTTI’s EB technology enhances tumor targeting through reversible albumin binding, delivering up to 26-fold greater tumor retention in preclinical models and approximately eight-fold higher tumor uptake in patients compared with conventional DOTA-TATE. These findings position the platform as a potentially transformative approach for next-generation radiopharmaceuticals, with the potential to improve efficacy, expand therapeutic opportunities, and create significant strategic value.

(Press release, Molecular Targeting Technologies, MAY 28, 2026, View Source [SID1234666175])

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

On May 28, 2026 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, reported enrollment of the first patients in SIgnatera-Guided iNterventionAL (SIGNAL)-ER 101, a prospective, single-arm, multi-center study evaluating Signatera MRD-guided de-escalation in early-stage breast cancer.

The current standard of care recommends two or three years of an adjuvant CDK4/6 inhibitor in combination with endocrine therapy for patients with intermediate-risk, hormone receptor (HR) positive, HER2 negative, early stage breast cancer. This is despite the fact that only ~3% of eligible patients derive benefit, over 60% of patients experience serious adverse events,1-2 and the U.S. retail costs can be over $400,000 for a full course of treatment. Meanwhile, data presented at SABCS 2025 from the PALLAS trial show that HR+ breast cancer patients who tested MRD-negative with Signatera had excellent long-term outcomes, with >95% distant recurrence-free interval at 5 years. This suggests that MRD-negative patients can safely defer CDK4/6 inhibition with no impact to clinical outcomes, with the provision that it be added if and when MRD is detected on serial testing using a TOMR (Treatment on MRD) approach.

SIGNAL-ER 101 plans to enroll approximately 725 patients across 50 sites in the United States. Patients who test MRD-positive will receive endocrine therapy plus CDK4/6 inhibitors, while those who test MRD-negative (the vast majority of patients) will receive endocrine therapy alone with quarterly Signatera monitoring. Patients who become MRD-positive during surveillance will be eligible to initiate CDK4/6 inhibition at that time, consistent with the TOMR approach.

"Many women with this type and stage of breast cancer are overtreated, which can have a profound impact on their quality of life," said Minetta Liu, M.D., chief medical officer, oncology and early cancer detection at Natera. "SIGNAL-ER 101 is a key part of our evidence generation roadmap, to support Signatera-guided treatment optimization without compromising the survival benefit from CDK4/6 inhibitors. This approach also allows patients to get the most effective treatment when Signatera shows it is necessary."

SIGNAL-ER 101 is the first in a series of innovative Natera-sponsored SIGNAL trials across multiple cancer types, designed to demonstrate that MRD-negative patients may be able to delay or defer treatment. There are many instances of overtreatment in cancer. This concept has already been studied in the IMvigor011 trial where MRD-negative patients with muscle-invasive bladder cancer achieved 97% overall survival at 2 years without any adjuvant therapy, and in the GALAXY and CALGB/SWOG 80702 trials, where MRD-negative patients with colorectal cancer saw no clinical benefit from adjuvant chemotherapy and celecoxib, respectively.

(Press release, Natera, MAY 28, 2026, View Source [SID1234666174])